<table>
<thead>
<tr>
<th>Title</th>
<th>The evidence of polymorphisms of the liver X receptor gene as a DNA-based biomarker for susceptibility to coronary artery disease in a Japanese population</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Fukae, Atsuki; Ikeda, Satoshi; Inoue, Mariko; Tachibana, Toshiko; Inamine, Tatsuo; Kondo, Shinji; Miyahara, Yoshiyuki; Maemura, Koji; Kohno, Shigeru; Tsukamoto, Kazuhiro</td>
</tr>
<tr>
<td>Citation</td>
<td>Acta Medica Nagasakiensia, 55(2), pp.69-76; 2011</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2011-03</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10069/24845">http://hdl.handle.net/10069/24845</a></td>
</tr>
</tbody>
</table>

NAOSITE: Nagasaki University’s Academic Output SITE
http://naosite.lb.nagasaki-u.ac.jp
The evidence of polymorphisms of the liver X receptor gene as a DNA-based biomarker for susceptibility to coronary artery disease in a Japanese population

Atsuki Fukae, Satoshi Ikeda, Mariko Ioue, Toshiko Tachibana, Tatsuo Inamine, Shinji Kondo, Yoshiyuki Miyahara, Koji Maemura, Shigeru Kohno, Kazuhiro Tsukamoto

Coronary artery disease (CAD) is a multifactorial and polygenic disorder, which arises due to atherosclerosis of the coronary arteries. Both numerous genetic factors and environmental risk factors may contribute to the pathogenesis of atherosclerosis. Thus, in order to identify the genetic determinants of CAD, an association of genetic polymorphisms of the liver X receptor-alpha (NR1H3) and -beta (NR1H2) genes with susceptibility to CAD was examined in a Japanese population. Eight tag single nucleotide polymorphisms (SNPs) in NR1H3 and NR1H2 were analyzed by PCR-restriction fragment length polymorphism or PCR-direct DNA sequencing method in 143 Japanese patients with CAD and 164 healthy control subjects with normal coronary arteries. Subsequently, haplotypes composed of the two tag SNPs in NR1H2 were constructed. Significant differences in the clinical risk factors, dyscholesteremia and diabetes mellitus, were observed between CAD patients and controls (P = 0.040 and P = 0.005, respectively). The frequencies of a C allele in the multiplicative model and its homozygous C/C genotype in the recessive model at rs2279238 in NR1H3 were significantly higher in CAD patients as compared to those in controls (P = 0.039 and P = 0.016, respectively). Furthermore, the frequency of a Hap 4/any diplotype of NR1H2 was significantly higher in CAD patients in comparison to controls (P = 0.0001, OR = 17.16). Multivariate logistic regression analysis revealed that these polymorphisms, dyscholesteremia, and diabetes mellitus independently contributed to susceptibility to CAD. In conclusion, NR1H3 and NR1H2 appears to be the genetic determinants of CAD. Furthermore, the genetic polymorphisms of NR1H3 and NR1H2 may be useful as new DNA-based diagnostic biomarkers for identifying high-risk individuals susceptible to CAD.

Address correspondence: Kazuhiro Tsukamoto, M.D., Ph.D., Department of Pharmacotherapeutics, Nagasaki University Graduate School of Biomedical Sciences, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan. Tel: +81-95-819-2447, Fax: +81-95-819-2895, e-mail: ktsuka@nagasaki-u.ac.jp

Received November 29, 2010; Accepted January 17, 2011

Keywords: single nucleotide polymorphism, liver X receptor gene, coronary artery disease, dyscholesteremia,
activating protein, and leukotriene A4 hydrolase, as well as chromosomal loci on numerous chromosomes (1, 2, 3, 6, 9, 10, 15, 16, 17, and X) for Caucasian populations. In particular, with regard to Japanese populations, platelet-activating factor acetylhydrolase, NADH/NADPH oxidase p22 phox, apolipoprotein C-III, connexin 37, fatty acid-binding protein 2, tumor necrosis factor-α, apolipoprotein E, adiponectin, BRCA1-associated protein, and megakaryoblastic leukemia factor-1 confer susceptibility to CAD in the Japanese populations.

Both cholesterol transporters and the cholesterol metabolic pathways are subject to a highly complex regulatory system for whole-body cholesterol homeostasis. Several transcription factors serve as key regulators of ATP-binding cassette (ABC) transporters and signaling molecules in the cholesterol metabolic pathways, which are involved in the pathogenesis of CAD. For example, the liver X receptors (LXRs), LXR-alpha (LXRA coded by NR1H3) and LXR-beta (LXRB coded by NR1H2), are members of the nuclear hormone receptor superfamily of transcription factors and respond to oxidized cholesterol derivatives (oxysterols) such as 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, and 25-epoxycholesterol. Ligand-activated LXRs form obligate heterodimers with retinoid X receptors and transcriptionally regulate the expression of target genes containing the LXR response elements. LXR-mediated gene activation decreases whole-body cholesterol accumulation, eventually leading to protection against atherosclerosis and hypercholesterolemia. Therefore, the dysregulation of the LXR signaling pathways may result in atherosclerosis and subsequent CAD.

In this study, a candidate gene-based association study was carried out by selecting LXRA (NR1H3) and LXRB (NR1H2) as candidate CAD-susceptibility genes. The purpose of this study was to investigate whether SNPs and their combination polymorphisms, which are referred to as haplotypes, in NR1H3 and NR1H2 are associated with susceptibility to the onset and/or development of CAD in a Japanese population, and whether such polymorphisms can be used as new genetic biomarkers for identifying high-risk individuals susceptible to CAD.

Methods
Subjects

All study subjects were Japanese who were unrelated to one another, and were enrolled from three general hospitals in Nagasaki, Japan, between October 2007 and October 2008. The subjects included 143 patients with CAD and 164 age- and gender-matched healthy individuals as control subjects. The clinical characteristics, including the clinical risk factors for CAD, at the end point of this study are shown in Table 1. The study protocol was approved by the Committee for Ethical Issues dealing with the Human Genome and Gene Analysis at Nagasaki University, and written informed consent was obtained from each subject.

Table 1. Clinical characteristics of CAD patients and control subjects

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>CAD patients</th>
<th>Control subjects</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>143</td>
<td>164</td>
<td></td>
</tr>
<tr>
<td>Age, mean ± SD (years)</td>
<td>67.9 ± 10.2</td>
<td>67.2 ± 9.9</td>
<td>0.458</td>
</tr>
<tr>
<td>Male/female (%)</td>
<td>98/45(68.5/31.5)</td>
<td>114/50(69.5/30.5)</td>
<td>0.853</td>
</tr>
<tr>
<td>BMI, mean ± SD (kg/m²)</td>
<td>23.9 ± 3.2</td>
<td>23.6 ± 3.2</td>
<td>0.688</td>
</tr>
<tr>
<td>Hypertension(present/absent)</td>
<td>101/42</td>
<td>113/51</td>
<td>0.743</td>
</tr>
<tr>
<td>dyscholesteremia(present/absent)</td>
<td>55/88</td>
<td>45/119</td>
<td>0.040</td>
</tr>
<tr>
<td>Smoking(present/absent)</td>
<td>53/90</td>
<td>46/118</td>
<td>0.092</td>
</tr>
<tr>
<td>Diabetes mellitus (present/absent)</td>
<td>36/107</td>
<td>21/143</td>
<td>0.005</td>
</tr>
</tbody>
</table>

*Characteristics were statistically compared by Mann-Whitney U test or chi-square test.

BMI was calculated on following formula: body weight (kg) / height X height (m).

Abbreviation: CAD, coronary artery disease; SD, standard deviation; BMI, body mass index.

The definite diagnosis of CAD was made on the basis of the presence of 75% stenosis in at least one of the three major coronary arteries revealed by coronary angiography (CAG). Control subjects were defined as having angiographically normal coronary arteries by CAG in spite of symptoms, e.g., chest oppressive feeling. Hypertension was defined as being under current treatment with antihypertensive agents, or as having systolic blood pressure of ≥ 140 mmHg and/or diastolic blood pressure of ≥ 90 mmHg. Dyscholesteremia was defined as being under current lipid-lowering therapy, or as having serum low-density lipoprotein cholesterol levels of ≥ 140 mg/dl or serum high density lipoprotein cholesterol levels of < 40 mg/dl. Current smokers were defined as smoking ≥ 10 cigarettes daily and regular smoking during the past 6 months. Diabetes mellitus was defined as currently undergoing treatment with insulin or oral antidiabetic agents, or as having the blood glucose levels of ≥ 126 mg/dl after an overnight fast.

Preparation of genomic DNA

Genomic DNA was extracted from whole blood samples using a QuickGene DNA Whole Blood Kit S (Fujifilm, Tokyo, Japan) with a QuickGene-800 (Fujifilm) according to the manufacturer's protocol.
Selection of tag SNPs in NR1H3 and NR1H2

All of SNPs in NR1H3 (GenBank accession number: U22662; MIM 602423) located on chromosome 11p11.2 and NR1H2 (GenBank accession number: U14534; MIM 600380) located on chromosome 19q13.3 were obtained using the Japanese data in Tokyo (Rel 24/phaseII Nov08, on NCBI B36 assembly, dbSNP b126) available on the International HapMap Web site. Candidate tag SNPs were selected from all SNPs in the each chromosomal region including 2-kb upstream with priority in minor allele frequency of more than 10% in the International HapMap data. Subsequently, genotyped tag SNPs were selected among the candidate tag SNPs were determined using the Haploview 4.1 software program. The gene structure and positions of genotyped tag SNPs in NR1H3 and NR1H2 are shown in Figure 1.

Genotyping of tag SNPs in NR1H3

Three SNPs, rs12221497 (the promoter region), rs2279238 (exon 3), and rs7120118 (intron 6) in NR1H3 were selected as genotyped tag SNPs for this study (Figure 1). The two tag SNPs, rs12221497 and rs2279238, were analyzed by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP). The polymorphic region was amplified by PCR with a GeneAmp System 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA) using 25 ng genomic DNA in a 25-μl reaction mixture containing 0.8X GoTaq Green master mix (Promega, Madison, WI, USA) and 15 pmol each of forward and reverse primers (Table 2). The amplification protocol consisted of initial denaturation at 95°C for 2 minutes, followed by 35 cycles of denaturation at 95°C for 30 seconds, annealing for 30 seconds at each temperature of selected primer pair (Table 2), and extension at 72°C for 30 seconds, and final extension at 72°C for 5 minutes. The PCR products were digested with each restriction enzyme (Table 2), separated by electrophoresis on a 6% polyacrylamide gel (Nacalai Tesque, Kyoto, Japan) for rs12221497 or a 2% ME-agarose gel (Nacalai Teque) for rs2279238, and subsequently visualized with an ultraviolet transilluminator (Alpha Innotech Co., San Leandro, CA, USA) after ethidium bromide staining.

The remaining rs7120118 SNP was analyzed by PCR-direct DNA sequencing method. The polymorphic region was amplified by PCR using 15 pmol each of forward and reverse primers (Table 2). The other constituents of the PCR mixture and the amplification protocol were the same as described above (Table 2). The PCR products were treated with ExoSAP-IT (Amersham Pharmacia Biotech, Piscataway, NJ, USA) and cycle sequenced using a BigDye Terminator v3.1 Cycle Sequencing FS Ready Reaction Kit (Applied Biosystems). The cycle sequencing was hot-started at 96°C for 30 seconds, followed by 25 cycles of denaturation

Table 2. The sequences of primer pairs and annealing temperature for PCR and restriciton enzyme for RFLP at each tag SNP

<table>
<thead>
<tr>
<th>Gene (NR1H3)</th>
<th>SNP</th>
<th>Analytic method</th>
<th>Sequence of forward primer (5’ to 3’)</th>
<th>Sequence of reverse primer (5’ to 3’)</th>
<th>Annealing temperature (°C)</th>
<th>Restriction enzyme</th>
</tr>
</thead>
<tbody>
<tr>
<td>LXRA</td>
<td>rs12221497</td>
<td>PCR-RFLP</td>
<td>GAGGAATCGCTGTGGCGAGCCAG</td>
<td>GCCACAAGGACATCTCTTCC</td>
<td>64</td>
<td>Msd I</td>
</tr>
<tr>
<td></td>
<td>rs2279238</td>
<td>PCR-RFLP</td>
<td>CTTCTCTGACCTCATTCCTTC</td>
<td>CGCACTGCAAGACTGTAG</td>
<td>62</td>
<td>Fnu4H I</td>
</tr>
<tr>
<td></td>
<td>rs7120118</td>
<td>Sequencing</td>
<td>TCCCCTCCTCTAGAATATCC</td>
<td>TTTTGAACAAGGCAAGAGTTG</td>
<td>60</td>
<td>-</td>
</tr>
<tr>
<td>LXRB (NR1H2)</td>
<td>rs2248949</td>
<td>PCR-RFLP</td>
<td>GCTAACAGCGGCTCAAGAAC</td>
<td>GTGGAGAGTGCTCCCTGTGCTG</td>
<td>63</td>
<td>Bam HI</td>
</tr>
<tr>
<td></td>
<td>rs1405655</td>
<td>PCR-RFLP</td>
<td>ATGAGACAAGGAGAGAGGAGGAGGAGGAGG</td>
<td>TGGTCTCTACGCACACACCAG</td>
<td>61</td>
<td>Xsp I</td>
</tr>
<tr>
<td></td>
<td>rs2303045</td>
<td>PCR-RFLP</td>
<td>GCTAACAGCGGCTCAAGAAC</td>
<td>GTGGAGAGTGCTCCCTGCTG</td>
<td>63</td>
<td>MspAI I</td>
</tr>
<tr>
<td></td>
<td>rs4802703</td>
<td>PCR-RFLP</td>
<td>CGTGGCTCTCTCTCTAGTGT</td>
<td>AGAATCCTGAAAGGAGG</td>
<td>60</td>
<td>Xsp I</td>
</tr>
<tr>
<td></td>
<td>rs2303044</td>
<td>PCR-RFLP</td>
<td>AGGGAGGGGTTGATAGAGAT</td>
<td>GAATCGAAGACAGGGTGA</td>
<td>61</td>
<td>Hae III</td>
</tr>
</tbody>
</table>

Abbreviation: PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism.
at 96°C for 10 seconds, annealing at 50°C for 5 seconds, and extension at 60°C for 4 minutes using 1 pmol PCR forward or reverse primer. After the sequencing reaction solutions were purified using Sephadex G-50 superfine columns (Amersham Pharmacia Biotech), the samples were dried and sequenced with an ABI Prism 3100 Genetic Analyzer (Applied Biosystems).

Genotyping of tag SNPs in NR1H2

Five SNPs, rs2248949 (intron 6), rs1405655 (intron 7), rs2303045 (intron 7), rs4802703 (intron 8), and rs2303044 (intron 8) in NR1H2 were selected as genotyped tag SNPs (Figure 1) and subsequently analyzed by PCR-RFLP using 15 pmol each of forward and reverse primers (Table 2). The other constituents of the PCR mixture and the amplification protocol were the same as described above. The PCR products were digested with each restriction enzyme (Table 2). The digests were then separated on a 2% agarose gel as described above.

Haplotype structures of NR1H2

The two tag SNPs in NR1H2, which showed a close association with susceptibility to CAD, were utilized to infer the haplotype structure and to analyze the haplotype frequency in an expectation-maximization algorithm using the SNP Alyze 7.0 standard software package (Dynacom Inc., Yokohama, Japan) in order to emphasize the variability and to enhance the power of detecting allelic association of rare variants.34,35

Statistical analysis

Differences in age and body mass index between CAD patients and control subjects were evaluated by Mann-Whitney U test using the SPSS 17 statistical software package (SPSS Japan Inc., Tokyo, Japan). Likewise, differences in gender and clinical risk factors between CAD patients and control subjects were compared by chi-square test using the Prism 5 statistical software package (GraphPad Software Inc., San Diego, CA, USA). In order to determine whether each SNP was in the Hardy-Weinberg equilibrium, a chi-square test with Yates’ correction was performed using the SNP Alyze 7.0 standard software package. The frequencies and distributions of haplotypes of NR1H2 were compared by logistic regression analysis using SPSS 17. Diplotype comparison of NR1H2 was analyzed by Fisher's exact test using Prism 5. Subsequently, a comparison of the genetic and clinical risk factors for susceptibility to CAD, which showed a statistically significant association with susceptibility to CAD by univariate analyses and were thereby selected as variables, between CAD patients and control subjects was carried out by multivariate logistic regression analysis using SPSS 17. The odds ratio (OR) with 95% confidence interval (CI) was calculated using SPSS 17. A P value of less than 0.05 was considered to be statistically significant.

Results

Comparison of the clinical characteristics between CAD patients and control subjects

The clinical characteristics of CAD patients were compared with those of control subjects (Table 1). Significant differences in two clinical risk factors, dyscholesteremia and diabetes mellitus, were observed between CAD patients and control subjects (P = 0.040 and P = 0.005, respectively). However, there were no significant differences in the other characteristics, such as the mean age, gender, mean body mass index, hypertension, and smoking (Table 1).

Association between tag SNPs in NR1H3 and susceptibility to CAD

The frequencies and distributions of genotypes at three tag SNPs in NR1H3 were identified (Table 3) and compared in three different genetic models (multiplicative, dominant, and recessive) between CAD patients and control subjects (Table 4). The distributions of these tag SNPs in NR1H3 among CAD patients and control subjects corresponded well to the Hardy-Weinberg equilibrium, thus implying that the subject base has a homogeneous genetic background.

One tag SNP, rs2279238, was significantly associated with susceptibility to CAD in two genetic models. The frequencies of the C minor allele in the multiplicative model and its homozygous C/C genotype in the recessive model at rs2279238 in CAD patients were significantly higher as compared to those in control subjects (P = 0.039 and P = 0.016, respectively; Table 4). No significant differences were observed in frequencies of other alleles and genotypes between CAD patients and control subjects.
Association between tag SNPs in NR1H2 and susceptibility to CAD

The frequencies and distributions of genotypes at five tag SNPs in NR1H2 were identified (Table 3) and compared in three genetic models between CAD patients and control subjects (Table 4). The distributions of these tag SNPs in NR1H2 among CAD patients and control subjects corresponded well to the Hardy-Weinberg equilibrium.

One tag SNP, rs1405655, were significantly associated with the lack of susceptibility to CAD in two genetic models. Whereas, another tag SNP, rs2303044, showed susceptibility to CAD in two genetic models. The frequencies of the homozygous T/C genotype and minor homozygous C/C genotype in the dominant model at rs1405655 were significantly decreased in CAD patients as compared to those in control subjects (P = 0.007; Table 4). In contrast, the frequencies of the homozygous C/T genotype and minor homozygous T/G genotype in the dominant model at rs2303044 were significantly increased in CAD patients in comparison to those in control subjects (P = 0.006; Table 4).

Table 3. Distributions of genotypes at tag SNPs in NR1H3 and NR1H2 between CAD patients and control subjects

<table>
<thead>
<tr>
<th>Gene</th>
<th>SNP</th>
<th>Genotype</th>
<th>Number (%) of genotypes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>CAD patients</td>
</tr>
<tr>
<td>LXRA</td>
<td>rs12221497</td>
<td>G/G</td>
<td>112(78.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>G/A</td>
<td>30(21.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A/A</td>
<td>1(0.7)</td>
</tr>
<tr>
<td></td>
<td>rs2279238</td>
<td>T/T</td>
<td>52(36.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C/T</td>
<td>63(44.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C/C</td>
<td>28(19.6)</td>
</tr>
<tr>
<td></td>
<td>rs7120118</td>
<td>C/C</td>
<td>71(49.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C/T</td>
<td>76(53.2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T/T</td>
<td>16(11.2)</td>
</tr>
<tr>
<td>NR1H3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>rs2248949</td>
<td>G/G</td>
<td>113(79.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>G/A</td>
<td>28(19.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A/A</td>
<td>2(1.4)</td>
</tr>
<tr>
<td></td>
<td>rs1405655</td>
<td>T/T</td>
<td>90(62.9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C/T</td>
<td>51(35.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C/C</td>
<td>2(1.4)</td>
</tr>
<tr>
<td></td>
<td>rs2303045</td>
<td>G/G</td>
<td>96(67.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>G/C</td>
<td>44(30.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C/C</td>
<td>3(2.1)</td>
</tr>
<tr>
<td></td>
<td>rs4802703</td>
<td>C/C</td>
<td>106(74.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C/A</td>
<td>36(25.2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A/A</td>
<td>1(0.7)</td>
</tr>
<tr>
<td></td>
<td>rs2303044</td>
<td>C/C</td>
<td>71(49.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C/T</td>
<td>66(46.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T/T</td>
<td>6(4.2)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td>143</td>
</tr>
</tbody>
</table>

Abbreviation: CAD, coronary artery disease.

Table 4. Allele and genotype comparison in three genetic models between CAD patients and control subjects

<table>
<thead>
<tr>
<th>Gene</th>
<th>SNP</th>
<th>Multiplicative model</th>
<th>Dominant model</th>
<th>Recessive model</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>OR (95% CI)</td>
<td>P value*</td>
<td>OR (95% CI)</td>
</tr>
<tr>
<td>LXRA</td>
<td>rs12221497</td>
<td>1.75(0.993-3.096)</td>
<td>0.051</td>
<td>1.786(0.980-3.257)</td>
</tr>
<tr>
<td></td>
<td>rs2279238</td>
<td>1.412(1.017-1.961)</td>
<td>0.039</td>
<td>1.337(0.843-2.114)</td>
</tr>
<tr>
<td></td>
<td>rs7120118</td>
<td>1.312(0.921-1.869)</td>
<td>0.132</td>
<td>1.233(0.787-1.934)</td>
</tr>
<tr>
<td></td>
<td>rs1405655</td>
<td>0.593(0.406-0.866)</td>
<td>0.007</td>
<td>0.534(0.338-0.844)</td>
</tr>
<tr>
<td></td>
<td>rs2303045</td>
<td>0.909(0.602-1.372)</td>
<td>0.650</td>
<td>1.026(0.635-1.656)</td>
</tr>
<tr>
<td></td>
<td>rs4802703</td>
<td>0.684(0.440-1.064)</td>
<td>0.091</td>
<td>0.692(0.422-1.135)</td>
</tr>
<tr>
<td></td>
<td>rs2303044</td>
<td>1.565(1.582-2.283)</td>
<td>0.020</td>
<td>1.905(1.203-3.012)</td>
</tr>
</tbody>
</table>

*Alleles and genotypes in three genetic models were compared by chi-square test or logistic regression analysis.

Abbreviation: CAD, coronary artery disease; OR, odds ratio; CI, confidence interval.
control subjects were divided into two subgroups according to the possession of a Hap 4 risk haplotype as an individual (Table 6). Fisher's exact test revealed that the possession of the Hap 4/any diplotype as an individual increased susceptibility to CAD ($P < 0.0001$, OR $= 17.16$, 95% CI $= 3.985 - 73.90$).

**Gene-gene and gene-environment interactions among genetic and clinical risk factors for susceptibility to CAD**

The two clinical risk factors, dyscholesteremia and diabetes mellitus, were selected as environmental variables by univariate analysis using chi-square test (Table 1). The two genetic factors, the C/C genotype at rs2279238 in $NR1H3$ and the Hap 4/any diplotype of $NR1H2$, were selected as genetic variables by chi-square test or Fisher's exact test (Tables 4 and 6). Thus, the gene-gene and gene-environment interactions were analyzed by multivariate logistic regression analysis between CAD patients and control subjects (Table 7). Multivariate analysis indicated that four variable risk factors, dyscholesteremia, diabetes mellitus, the C/C genotype at rs2279238 in $NR1H3$, and the Hap 4/any diplotype of $NR1H2$, independently contributed to susceptibility to CAD ($P = 0.036$, $P = 0.008$, $P = 0.022$, and $P < 0.0001$, respectively; Table 7).

### Table 5. Distributions of haplotypes of $NR1H2$ between CAD patients and control subjects

<table>
<thead>
<tr>
<th>Gene Haplotype</th>
<th>SNP</th>
<th>Number (%) of haplotypes</th>
<th>Haplotype comparison*</th>
</tr>
</thead>
<tbody>
<tr>
<td>$NR1H2$</td>
<td></td>
<td></td>
<td>Control subjects</td>
</tr>
<tr>
<td>Hap 1</td>
<td>T</td>
<td>204 (71.3)</td>
<td>232 (70.7)</td>
</tr>
<tr>
<td>Hap 2</td>
<td>C</td>
<td>51 (17.8)</td>
<td>63 (19.2)</td>
</tr>
<tr>
<td>Hap 3</td>
<td>C</td>
<td>4 (1.4)</td>
<td>31 (9.5)</td>
</tr>
<tr>
<td>Hap 4</td>
<td>T</td>
<td>27 (9.4)</td>
<td>2 (0.6)</td>
</tr>
</tbody>
</table>

**Total number of haplotypes** 286 328

*Each haplotype was compared with other haplotypes combined by logistic regression analysis.

Abbreviation: CAD, coronary artery disease; OR, odds ratio; CI, confidence interval.

### Table 6. Diplotype comparison of susceptibility to CAD between CAD patients and control subjects

<table>
<thead>
<tr>
<th>Gene Haplotype</th>
<th>Diplotype</th>
<th>Number (%) of diplotypes</th>
<th>Diplotype comparison*</th>
</tr>
</thead>
<tbody>
<tr>
<td>$NR1H2$</td>
<td>Hap 4/any</td>
<td>25 (17.5)</td>
<td>17.16 (3.985-73.90)</td>
</tr>
<tr>
<td>Other diplotypes</td>
<td>118 (82.5)</td>
<td>162 (98.8)</td>
<td>&lt; 0.0001</td>
</tr>
</tbody>
</table>

**Total number of participants** 143 164

*Diplotype comparison was statistically analyzed by Fisher's exact test.

Abbreviation: CAD, coronary artery disease; OR, odds ratio; CI, confidence interval.

### Table 7. The gene-gene and gene-environment interactions among $NR1H3$ genotype, $NR1H2$ diplotype, dyscholesteremia, and diabetes mellitus for susceptibility to CAD

<table>
<thead>
<tr>
<th>Factor</th>
<th>Factor comparison*</th>
</tr>
</thead>
<tbody>
<tr>
<td>dyscholesteremia</td>
<td>1.719 (1.036-2.852)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>2.316 (1.248-4.299)</td>
</tr>
<tr>
<td>C/C genotype at rs2279238 in $NR1H3$</td>
<td>2.231 (1.121-4.440)</td>
</tr>
<tr>
<td>Hap 4/any diplotype of $NR1H2$</td>
<td>19.267 (4.258-87.176)</td>
</tr>
</tbody>
</table>

*Factors were statistically analyzed by multivariate logistic regression analysis.

Abbreviation: CAD, coronary artery disease; OR, odds ratio; CI, confidence interval.

### Discussion

This study is the first to demonstrate that an association between $NR1H3$ and $NR1H2$ polymorphisms and susceptibility to CAD in the Japanese population. The possession of the C/C genotype at rs2279238 in $NR1H3$ or the Hap 4/any diplotype of $NR1H2$ conferred increased susceptibility to CAD. Furthermore, the genetic polymorphisms, the C/C genotype at rs2279238 in $NR1H3$ and the Hap 4/any diplotype of $NR1H2$, as well as co-morbidities of dyscholesteremia and/or diabetes mellitus, independently contributed to the onset and/or development of CAD. In particular, the possession of the Hap 4/any diplotype of $NR1H2$ indicated an
approximately 19-fold increase in the odds ratio for CAD in this study (Table 7), although such CAD patients account for only approximately 17.5% (25/143 = 17.5% in Table 6) of the genetic variance observed in CAD. These findings suggest that NR1H3 and NR1H2 are genetic determinants of predisposition to the onset and/or development of CAD in Japanese individuals. However, it remains to be confirmed whether this association is reproducible in a large number of Japanese subjects as well as other ethnic populations because this study population was very small. Additional studies are needed because different populations will often have different allele frequencies and haplotype structures.

Ligand-activated LXRs (LXRA and LXRβ) regulate a set of target genes related to a decrease in whole-body cholesterol accumulation by inhibiting intestinal cholesterol absorption through ABC transporters, ABCG5 and ABCG8, and by inhibiting cholesterol transfer from peripheral tissues.30-32 In addition, the activation of LXR-mediated signals leads to an increase in cholesterol efflux from macrophages through ABCA1 and ABCG1,33-35 uptake from serum into the liver by apolipoprotein E,4 catabolism from cholesterol into bile acids by cholesterol 7-alpha-hydroxylase in the hepatocytes,41 and biliary secretion of cholesterol into the bile ducts through ABCG5 and ABCG8 in the hepatocytes.42-44 Taken together, the LXR signaling pathways are endogenous inhibitors of atherosclerosis. Therefore, it seems likely to speculate that the polymorphisms of NR1H3 and NR1H2, especially the C/C genotype at rs2279238 in NR1H3 and the Hap 4/any diplotype of NR1H2, may diminish the function of LXRs by reducing the expression of these target genes, decreasing their affinity for the DNA binding site, and/or altering their interactions with other nuclear receptors such as retinoid X receptor.45-47 This process may alter the efficiency of the LXR-medicated signals, thus indicating that a decrease in anti-atherogenic factors can lead to the progression to coronary atherosclerosis, although the potential mechanisms of action of the NR1H3 and NR1H2 polymorphisms identified in this study remain unknown.

In particular, atherosclerosis of the coronary arteries is focused on macrophage. Atherosclerosis is attributed to progressive plaque formation, finally resulting in the thickening and hardening of the coronary arteries and eventually developing the predisposition to CAD.

Conclusions

NR1H3 and NR1H2 appear to be genetic determinants for susceptibility to CAD in the Japanese population. These genetic polymorphisms of NR1H3 and NR1H2 may therefore be useful as new DNA-based diagnostic biomarkers for identifying high-risk individuals susceptible to CAD. Finally, LXRs, especially their agonists, may be good target molecules for the development of novel drugs in the future.

Acknowledgements

The authors thank to the physicians, patients, and healthy control subjects for participating in this study. This work was supported by a research grant from the Non Profit Organization Aimed to Support Community Medicine Research in Nagasaki, Japan (K Tsukamoto).

References

6. Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared
7. Hamsten A, Eriksson P. Identifying the susceptibility genes for coro-

nary artery disease: from hyperbole through doubt to cautious opti-
polymorphism in the CD41 promoter decreases the affinity of Sp pro-
tein binding and enhances transcriptional activity. J Immunol
167:5838-5844, 2001
9. Arroyo-Espiguero R, Avanzas P, Jeffery S, Kaski JC. CD41 and toll-
lke receptor 4: a link between infection and acute coronary events?
Heart 90:983-988, 2004
in the lympho
gene that are associated with susceptibility to myocardial infarction.
Nat Genet 32:650-654, 2002
5-lipoxygenase activating protein confers risk of myocardial infarc-
encoding 1-lymphotxin-β confers ethnicity-specific risk of myocardi-
2 and X for premature coronary heart disease identified in early-
and late-settlement populations of Finland. Am J Hum Genet
67:1481-1493, 2000

nary artery disease suggests in Indo-Mauritians a susceptibility
locus on chromosome 16p13 and replicates linkage with the metabolic
susceptibility locus on chromosome 1p34-36 identified by genomewide
16. Farrall M, Green FR, Pedersen JF, et al. Genome-wide mapping of sus-
cceptibility to coronary artery disease identified a novel2
chromosome 9p21 affects the risk of myocardial infarction.
Science 316:1482-1487, 2007
on chromosome 9p21 affects the risk of myocardial infarction. Science
316:1491-1493, 2007
polymorphisms with coronary artery disease in individuals with or
without nonfamilial hypercholesterolemia. Atherosclerosis
172:167-173, 2004
disease in individuals with or without type 2 diabetes. Mol Genet
Metab 81:282-290, 2004
associated with the metabolic syndrome and coronary artery disease. J
Am Coll Cardiol 43:1195-1200, 2004
disease factors in East Asian populations replicated the association
mia factor-1 gene is associated with susceptibility to coronary artery disease. Hum
Genet 126:539-547, 2009
24. Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in
the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol
16:459-481, 2000
25. Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in
26. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and
27. Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf
DJ. LXR, a nuclear receptor that defines a distinct retinoid response
28. Song C, Kokontis JM, Hiipakka RA, Liao S. Ubiquitous receptor: a
receptor that modulates gene activation by retinoic acid and thyroid hor-
mon receptors. Proc Natl Acad Sci USA 91:10809-10813, 1994
29. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An
oxygen signalling pathway mediated by the nuclear receptor LXR .
receptor LXR by oxysterols defines a new hormone response pathway.
31. The international HapMap Consortium. A second generation human
32. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visual-
33. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES. High-
resolution haplotype structure in the human genome. Nat Genet
29:229-232, 2001
34. Johnson GCL, Esposito L, Barrett BJ, et al. Haplotype tagging for
35. Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf
DJ. Regulation of ATP-binding cassette sterol transporters ABCG5
and ABCG8 by the liver X receptors . J Biol Chem 277:18793-
18800, 2002
36. Yu L, Hammer RE, Li-Hawkins J, et al. Disruption of Abcg5 and
Abcg8 in mice reveals their crucial role in biliary cholesterol secretion.
Proc Natl Acad Sci USA 99:16237-16242, 2002
and ABCG8 promotes biliary cholesterol secretion and reduces frac-
tional absorption of dietary cholesterol. J Clin Invest 110:671-680,
2002
38. Repa JJ, Turley SD, Lobaccaro JA, et al. Regulation of absorption and
ABCB1-mediated efflux of cholesterol by RXR heterodimers. Science
289:1524-1529, 2000
39. Sabol SL, Brewere HB Jr, Santamaria-FOjo S. The human ABCG1
gene: identification of LXR response elements that modulate expres-
40. Lewis GF, Rader DJ. New insights into the regulation of HDL metabo-
41. Chiang YJL, Kimmel R, Stroup D. Regulation of cholesterol 7β-
hydroxylase gene (CYP7A1) transcription by the liver orphan receptor
42. Shulman AI, Mangelsdorf DJ. Retinoid X receptor heterodimers in
43. Shin WS, Szuba A, Rockson SG. The role of chemokines in human
cardiocvascular pathology; enhanced biological insights. Atherosclerosis
160:91-102, 2002
suppress vascular smooth muscle cell proliferation and inhibit neointima
formation in balloon-injured rat carotid arteries. Circ Res 95:e110-
K, 2004
45. Bobryshev YV. Monocyte recruitment and foam cell formation in
46. Saxena U, Goldberg JD. Endothelial cells and atherosclerosis: lipopro-
ein metabolism, matrix interaction and monocyte recruitment. Curr
Opin Lipidol 5:316-322, 1994
47. Joseph SB, Castrillo A, Laffitte BA, et al. Reciprocal regulation of in-
flammation and lipid metabolism by liver X receptors. Nat Med 9:213-
219, 2003
48. Valledor AF, Hsu LC, Ogawa S, et al. Activation of liver X receptors
and retinoid X receptors prevents bacterial-induced macrophage apoptosis.
Proc Natl Acad Sci USA 101:17813-17818, 2004
49. Tabas I. Consequences and therapeutic implications of macrophage
apoptosis in atherosclerosis: the important lesion stage and phagocytic
50. Joseph SB, McKillingin E, Pei L, et al. Synthetic LXR ligand inhibits
the development of atherosclerosis in mice. Proc Natl Acad Sci USA
99:7604-7609, 2002
Kazuhiro Tsukamoto et al.: Polymorphisms of LXR gene in CAD